Tissular Tregs: A unique population of adipose-tissue-resident Foxp3+CD4+ T cells that impacts organismal metabolism

Seminars in Immunology

Volumn 23, Issue 6, 2011, Pages 431-437

  Cipolletta, Daniela ^a   Kolodin, Dmitriy ^a   Benoist, Christophe ^a   Mathis, Diane ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adipose tissue; Inflammation; Obesity; Regulatory T cells; Type 2 diabetes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; BODY FAT; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION;

ADIPOSE TISSUE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 2; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; OBESITY; T-LYMPHOCYTES, REGULATORY;

EID: 82755182907     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2011.06.002     Document Type: Review

References (96)

1. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
2. Mor A., Planer D., Luboshits G., Afek A., Metzger S., Chajek-Shaul T., et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:893-900.
3. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
4. Xie J.J., Wang J., Tang T.T., Chen J., Gao X.L., Yuan J., et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010, 49:185-193.
5. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009, 15:930-939.
6. Deiuliis J., Shah Z., Shah N., Needleman B., Mikami D., Narula V., et al. Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers. PLoS One 2011, 6:e16376.
7. Center for Disease Control and Prevention 2011 National diabetes fact sheet 2011.
8. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
9. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
10. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
11. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11:85-97.
12. Jager J., Gremeaux T., Cormont M., Le Marchand-Brustel Y., Tanti J.F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007, 148:241-251.
13. Rotter V., Nagaev I., Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003, 278:45777-45784.
14. Han C.Y., Subramanian S., Chan C.K., Omer M., Chiba T., Wight T.N., et al. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes 2007, 56:2260-2273.
15. Kamei N., Tobe K., Suzuki R., Ohsugi M., Watanabe T., Kubota N., et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006, 281:26602-26614.
16. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
17. Halberg N., Khan T., Trujillo M.E., Wernstedt-Asterholm I., Attie A.D., Sherwani S., et al. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 2009, 29:4467-4483.
18. Minamino T., Orimo M., Shimizu I., Kunieda T., Yokoyama M., Ito T., et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med 2009, 15:1082-1087.
19. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
20. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
21. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283:1544-1548.
22. Feinstein R., Kanety H., Papa M.Z., Lunenfeld B., Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993, 268:26055-26058.
23. Elgazar-Carmon V., Rudich A., Hadad N., Levy R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res 2008, 49:1894-1903.
24. Liu J., Divoux A., Sun J., Zhang J., Clement K., Glickman J.N., et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009, 15:940-945.
25. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005, 46:2347-2355.
26. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
27. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
28. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
29. Fujisaka S., Usui I., Bukhari A., Ikutani M., Oya T., Kanatani Y., et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009, 58:2574-2582.
30. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184.
31. Lumeng C.N., Deyoung S.M., Bodzin J.L., Saltiel A.R. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 56:16-23.
32. Shaul M.E., Bennett G., Strissel K.J., Greenberg A.S., Obin M.S. Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high-fat diet-induced obesity in mice. Diabetes 2010, 59:1171-1181.
33. Herrero L., Shapiro H., Nayer A., Lee J., Shoelson S.E. Inflammation and adipose tissue macrophages in lipodystrophic mice. Proc Natl Acad Sci U S A 2010, 107:240-245.
34. Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011, 17:179-188.
35. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
36. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
37. Rajamaki K., Lappalainen J., Oorni K., Valimaki E., Matikainen S., Kovanen P.T., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
38. Nguyen M.T., Favelyukis S., Nguyen A.K., Reichart D., Scott P.A., Jenn A., et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007, 282:35279-35292.
39. Kintscher U., Hartge M., Hess K., Foryst-Ludwig A., Clemenz M., Wabitsch M., et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008, 28:1304-1310.
40. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009, 15:914-920.
41. Yang H., Youm Y.H., Vandanmagsar B., Ravussin A., Gimble J.M., Greenway F., et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J Immunol 2010, 185:1836-1845.
42. Winer S., Chan Y., Paltser G., Truong D., Tsui H., Bahrami J., et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009, 15:921-929.
43. Strissel K.J., DeFuria J., Shaul M.E., Bennett G., Greenberg A.S., Obin M.S. T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice. Obesity (Silver Spring) 2010, 18:1918-1925.
44. Rocha V.Z., Folco E.J., Sukhova G., Shimizu K., Gotsman I., Vernon A.H., et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 2008, 103:467-476.
45. Lord G.M., Matarese G., Howard J.K., Baker R.J., Bloom S.R., Lechler R.I. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998, 394:897-901.
46. Wang Y., Souabni A., Flavell R.A., Wan Y.Y. An intrinsic mechanism predisposes Foxp3-expressing regulatory T cells to Th2 conversion in vivo. J Immunol 2010, 185:5983-5992.
47. Mombaerts P., Iacomini J., Johnson R.S., Herrup K., Tonegawa S., Papaioannou V.E. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992, 68:869-877.
48. Powrie F., Leach M.W., Mauze S., Menon S., Caddle L.B., Coffman R.L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994, 1:553-562.
49. Davidson N.J., Leach M.W., Fort M.M., Thompson-Snipes L., Kuhn R., Muller W., et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996, 184:241-251.
50. Feng T., Wang L., Schoeb T.R., Elson C.O., Cong Y. Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med 2010, 207:1321-1332.
51. Rausch M.E., Weisberg S., Vardhana P., Tortoriello D.V. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) 2008, 32:451-463.
52. Duffaut C., Galitzky J., Lafontan M., Bouloumie A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun 2009, 384:482-485.
53. Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 2011, 17:610-617.
54. Ngo V.N., Cornall R.J., Cyster J.G. Splenic T zone development is B cell dependent. J Exp Med 2001, 194:1649-1660.
55. Baumgarth N., Jager G.C., Herman O.C., Herzenberg L.A. CD4+ T cells derived from B cell-deficient mice inhibit the establishment of peripheral B cell pools. Proc Natl Acad Sci U S A 2000, 97:4766-4771.
56. Linton P.J., Harbertson J., Bradley L.M. A critical role for B cells in the development of memory CD4 cells. J Immunol 2000, 165:5558-5565.
57. Hill J.A., Feuerer M., Tash K., Haxhinasto S., Perez J., Melamed R., et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 2007, 27:786-800.
58. Feuerer M., Hill J.A., Kretschmer K., von Boehmer H., Mathis D., Benoist C. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc Natl Acad Sci U S A 2010, 107:5919-5924.
59. Lin W., Haribhai D., Relland L.M., Truong N., Carlson M.R., Williams C.B., et al. Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 2007, 8:359-368.
60. Gavin M.A., Rasmussen J.P., Fontenot J.D., Vasta V., Manganiello V.C., Beavo J.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007, 445:771-775.
61. Feuerer M., Hill J.A., Mathis D., Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009, 10:689-695.
62. Zheng Y., Chaudhry A., Kas A., Deroos P., Kim J.M., Chu T.T., et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 2009, 458:351-356.
63. Chaudhry A., Rudra D., Treuting P., Samstein R.M., Liang Y., Kas A., et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009, 326:986-991.
64. Koch M.A., Tucker-Heard G., Perdue N.R., Killebrew J.R., Urdahl K.B., Campbell D.J. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009, 10:595-602.
65. Tran T.T., Yamamoto Y., Gesta S., Kahn C.R. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 2008, 7:410-420.
66. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
67. Thorburn J., Frankel A.E., Thorburn A. Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. Clin Cancer Res 2003, 9:861-865.
68. Boyman O., Kovar M., Rubinstein M.P., Surh C.D., Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927.
69. Pelleymounter M.A., Cullen M.J., Baker M.B., Hecht R., Winters D., Boone T., et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269:540-543.
70. Klebig M.L., Wilkinson J.E., Geisler J.G., Woychik R.P. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci U S A 1995, 92:4728-4732.
71. Matarese G., Procaccini C., De R.V., Horvath T.L., La C.A. Regulatory T cells in obesity: the leptin connection. Trends Mol Med 2010, 16:247-256.
72. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404:661-671.
73. Matarese G., Di G.A., Sanna V., Lord G.M., Howard J.K., Di T.A., et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 2001, 166:5909-5916.
74. De R.V., Procaccini C., Cali G., Pirozzi G., Fontana S., Zappacosta S., et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007, 26:241-255.
75. Wigren M., Bengtsson D., Duner P., Olofsson K., Bjorkbacka H., Bengtsson E., et al. Atheroprotective effects of alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ Res 2009, 104:e62-e70.
76. Gotsman I., Grabie N., Gupta R., Dacosta R., MacConmara M., Lederer J., et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114:2047-2055.
77. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., van der Wal A.C. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2:e779.
78. Baecher-Allan C., Anderson D.E. Regulatory cells and human cancer. Semin Cancer Biol 2006, 16:98-105.
79. Belkaid Y., Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 2005, 6:353-360.
80. Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005, 175:8392-8400.
81. Baecher-Allan C., Viglietta V., Hafler D.A. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004, 16:89-98.
82. Taylor P.A., Noelle R.J., Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001, 193:1311-1318.
83. Borish L., Aarons A., Rumbyrt J., Cvietusa P., Negri J., Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996, 97:1288-1296.
84. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199:971-979.
85. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277-285.
86. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004, 199:1455-1465.
87. Tarbell K.V., Yamazaki S., Olson K., Toy P., Steinman R.M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide suppress autoimmune diabetes. J Exp Med 2004, 199:1467-1477.
88. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007, 7:622-632.
89. Ilan Y., Maron R., Tukpah A.M., Maioli T.U., Murugaiyan G., Yang K., et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A 2010, 107:9765-9770.
90. Margalit M., Shalev Z., Pappo O., Sklair-Levy M., Alper R., Gomori M., et al. Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice. J Pharmacol Exp Ther 2006, 319:105-110.
91. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A.S., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+. Nat Med 2006, 12:627-635.
92. Ishikawa H., Ochi H., Chen M.L., Frenkel D., Maron R., Weiner H.L. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 2007, 56:2103-2109.
93. Wu H.Y., Center E.M., Tsokos G.C., Weiner H.L. Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus 2009, 18:586-596.
94. La C.A., Van K.L., Fu D.S. CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol 2006, 27:322-327.
95. Steffens S., Burger F., Pelli G., Dean Y., Elson G., Kosco-Vilbois M., et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 2006, 114:1977-1984.
96. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.